Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Page 1
Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS.
Cotter G, Davison BA, Milo O, Bourge RC, Cleland JG, Jondeau G, Krum H, O'Connor CM, Metra M, Parker JD, Torre-Amione G, van Veldhuisen DJ, Kobrin I, Rainisio M, Senger S, Edwards C, McMurray JJ, Teerlink JR; VERITAS Investigators. Cotter G, et al. Among authors: rainisio m. J Card Fail. 2016 Oct;22(10):815-22. doi: 10.1016/j.cardfail.2015.12.017. Epub 2015 Dec 22. J Card Fail. 2016. PMID: 26721775 Clinical Trial.
CONCLUSIONS: In patients who have been admitted for AHF, longer length of hospital stay is associated with a higher rate of short-term mortality. CLINICAL TRIAL REGISTRATION: VERITAS-1 and -2: Clinicaltrials.gov identifiers NCT00525707 and NCT00524433....
CONCLUSIONS: In patients who have been admitted for AHF, longer length of hospital stay is associated with a higher rate of short-term …
Echocardiographic ejection fraction in patients with acute heart failure: correlations with hemodynamic, clinical, and neurohormonal measures and short-term outcome.
Uriel N, Torre-Amione G, Milo O, Kaluski E, Perchenet L, Blatt A, Kobrin I, Turnovski A, Kaplan S, Rainisio M, Frey A, Vered Z, Cotter G. Uriel N, et al. Among authors: rainisio m. Eur J Heart Fail. 2005 Aug;7(5):815-9. doi: 10.1016/j.ejheart.2004.10.013. Eur J Heart Fail. 2005. PMID: 16087136 Free article.
Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.
Sitbon O, McLaughlin VV, Badesch DB, Barst RJ, Black C, Galiè N, Humbert M, Rainisio M, Rubin LJ, Simonneau G. Sitbon O, et al. Among authors: rainisio m. Thorax. 2005 Dec;60(12):1025-30. doi: 10.1136/thx.2005.040618. Epub 2005 Jul 29. Thorax. 2005. PMID: 16055621 Free PMC article.
CONCLUSIONS: No evidence was found to suggest that initial treatment with oral bosentan, followed by or with the addition of other treatment if needed, adversely affected the long term outcome compared with initial intravenous epoprostenol in patients with class III idiopa …
CONCLUSIONS: No evidence was found to suggest that initial treatment with oral bosentan, followed by or with the addition of other treatment …
Survival with first-line bosentan in patients with primary pulmonary hypertension.
McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galiè N, Rainisio M, Simonneau G, Rubin LJ. McLaughlin VV, et al. Among authors: rainisio m. Eur Respir J. 2005 Feb;25(2):244-9. doi: 10.1183/09031936.05.00054804. Eur Respir J. 2005. PMID: 15684287 Free article. Clinical Trial.
The orally active, dual endothelin receptor antagonist bosentan improves exercise endurance, haemodynamics, and functional class over the short term. To determine the effect of first-line bosentan therapy on survival, this study followed 169 patients with PPH treated with …
The orally active, dual endothelin receptor antagonist bosentan improves exercise endurance, haemodynamics, and functional class over the sh …
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.
Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Hervé P, Rainisio M, Simonneau G. Sitbon O, et al. Among authors: rainisio m. J Am Coll Cardiol. 2002 Aug 21;40(4):780-8. doi: 10.1016/s0735-1097(02)02012-0. J Am Coll Cardiol. 2002. PMID: 12204511 Free article. Clinical Trial.
OBJECTIVES: We sought to determine the factors associated with long-term survival in patients with primary pulmonary hypertension (PPH) treated with continuous epoprostenol infusion. ...
OBJECTIVES: We sought to determine the factors associated with long-term survival in patients with primary pulmonary hypertension (PP …
A case-controlled study with dornase alfa to evaluate impact on disease progression over a 4-year period.
Shah PL, Conway S, Scott SF, Rainisio M, Wildman M, Stableforth D, Hodson ME. Shah PL, et al. Among authors: rainisio m. Respiration. 2001;68(2):160-4. doi: 10.1159/000050486. Respiration. 2001. PMID: 11287830
Recombinant human DNase I (dornase alfa) reduces the viscoelasticity of airway secretions and hence may improve clearance of airway secretions. OBJECTIVES: To evaluate the long-term influence of dornase alfa on disease progression by performing a case-controlled study with …
Recombinant human DNase I (dornase alfa) reduces the viscoelasticity of airway secretions and hence may improve clearance of airway secretio …
Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Epidemiologic Registry of Cystic Fibrosis.
Mastella G, Rainisio M, Harms HK, Hodson ME, Koch C, Navarro J, Strandvik B, McKenzie SG. Mastella G, et al. Among authors: rainisio m. Eur Respir J. 2000 Sep;16(3):464-71. doi: 10.1034/j.1399-3003.2000.016003464.x. Eur Respir J. 2000. PMID: 11028661 Free article.
However, any clear independent influence of allergic bronchopulmonary aspergillosis on the rate of lung function decline in the short term was not shown....
However, any clear independent influence of allergic bronchopulmonary aspergillosis on the rate of lung function decline in the short ter …